Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMaria GavriatopoulouANAjay K. NookaMDMeletios Α. Dimopoulos

Discussion

Loading...

Member takes

Overview

Analysis reveals impacts of daratumumab and clinical characteristics on patient outcomes in NDMM, suggesting tailored approaches are essential.

Key Points

  • To identify factors associated with decreased overall survival in NDMM patients who fail to achieve VGPR.
  • Combined data from Emory Myeloma Database and Athens, Greece dataset totaling 462 patients.
  • Patients treated with daratumumab, lenalidomide, bortezomib, and dexamethasone induction therapy.
  • Evaluated responses per International Myeloma Working Group Uniform Response Criteria and used SPSS for analysis.
  • 112 patients (24.2%) failed to achieve VGPR; estimated OS was 65% at four years.
  • Factors linked to failure included t(11;14) and del13q, but not del17p or other clinical factors.
  • Median PFS was 31.2 months, with del17p, ISS stage, and transplant status affecting survival.

Cite This Study

Gavriatopoulou et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e344https://doi.org/10.1182/blood-2025-407
View Full Paper
Ask AI
Bookmark
Share